ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded up 13.9% on Thursday . The stock traded as high as GBX 4.39 and last traded at GBX 4.10. Approximately 1,246,992 shares traded hands during trading, a decline of 52% from the average session volume of 2,587,690 shares. The stock had previously closed at GBX 3.60.
ImmuPharma Trading Up 13.9%
The stock has a 50 day moving average price of GBX 4.10 and a two-hundred day moving average price of GBX 5.09. The company has a market cap of £25.58 million, a price-to-earnings ratio of -11.08 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last posted its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. On average, equities analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
